{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:12:45Z","timestamp":1789841565745,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ejca.2023.113245","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T13:27:33Z","timestamp":1689859653000},"page":"113245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study"],"prefix":"10.1016","volume":"192","author":[{"given":"Hans","family":"Gelderblom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-120X","authenticated-orcid":false,"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1284-8493","authenticated-orcid":false,"given":"Suzanne","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6158-890X","authenticated-orcid":false,"given":"Margaret","family":"von Mehren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Zalcberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Koo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albiruni Abdul","family":"Razak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Trent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Le Cesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany L.","family":"Siontis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5552-6283","authenticated-orcid":false,"given":"Kjetil","family":"Boye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeltje","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Druta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0146-7732","authenticated-orcid":false,"given":"Neeta","family":"Somaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0159-5531","authenticated-orcid":false,"given":"Ping","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3998-3417","authenticated-orcid":false,"given":"Brooke","family":"Harrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Reichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3057-7735","authenticated-orcid":false,"given":"Rodrigo","family":"Ruiz-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5949-8120","authenticated-orcid":false,"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.113245_bib1","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(07)60780-6","article-title":"Gastrointestinal stromal tumour","volume":"369","author":"Rubin","year":"2007","journal-title":"The Lancet"},{"key":"10.1016\/j.ejca.2023.113245_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canep.2015.10.031","article-title":"Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies","volume":"40","author":"Soreide","year":"2016","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.ejca.2023.113245_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020493","article-title":"Gastrointestinal stromal tumours (GISTs): novel therapeutic strategies with immunotherapy and small molecules","volume":"22","author":"Vallilas","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2023.113245_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13045-020-01026-6","article-title":"The management of metastatic GIST: current standard and investigational therapeutics","volume":"14","author":"Kelly","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ejca.2023.113245_bib5","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1126\/science.1079666","article-title":"PDGFRA activating mutations in gastrointestinal stromal tumours","volume":"299","author":"Heinrich","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.ejca.2023.113245_bib6","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumours expressing the kit receptor tyrosine kinase: S0033","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113245_bib7","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"The Lancet"},{"key":"10.1016\/j.ejca.2023.113245_bib8","unstructured":"Pfizer Labs: Sutent (Sunitinib Malate) capsules for oral use. Prescribing information, 2021."},{"key":"10.1016\/j.ejca.2023.113245_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13569-019-0123-4","article-title":"Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre","volume":"10","author":"Chamberlain","year":"2020","journal-title":"Clin Sarcoma Res"},{"key":"10.1016\/j.ejca.2023.113245_bib10","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.113245_bib11","unstructured":"Deciphera Pharmaceuticals LLC: QINLOCK (Ripretinib) tablets: US prescribing information, 2021."},{"issue":"738\u2013751","key":"10.1016\/j.ejca.2023.113245_bib12","article-title":"Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants","volume":"35","author":"Smith","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2023.113245_bib13","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.2016.71.0228","volume":"35","author":"Casali","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113245_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071832","article-title":"Health-related quality of life and side effects in gastrointestinal stromal tumour (GIST) patients treated with tyrosine kinase inhibitors: a systematic review of the literature","volume":"14","author":"van de Wal","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2023.113245_bib15","article-title":"Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: cross-sectional results of a German multicentre observational study (PROSa)","volume":"30","author":"Eichler","year":"2021","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.ejca.2023.113245_bib16","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.21.02810","article-title":"The time toxicity of cancer treatment","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113245_bib17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13569-019-0116-3","article-title":"Perspectives on treatment side effects in patients with metastatic gastrointestinal stromal tumour: a qualitative study","volume":"9","author":"Fauske","year":"2019","journal-title":"Clin Sarcoma Res"},{"key":"10.1016\/j.ejca.2023.113245_bib18","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options","volume":"33","author":"Schnipper","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113245_bib19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40271-021-00542-y","article-title":"FDA guidance on assessment of patient-reported outcomes in cancer trials: a breath of fresh air or a storm in a teacup?","volume":"14","author":"Gnanasakthy","year":"2021","journal-title":"Patient"},{"key":"10.1016\/j.ejca.2023.113245_bib20","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-magnitude of clinical benefit scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2023.113245_bib21","doi-asserted-by":"crossref","first-page":"9519","DOI":"10.1038\/s41598-017-09132-1","article-title":"Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients","volume":"7","author":"Schvartsman","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2023.113245_bib22","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.ejca.2009.02.011","article-title":"Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure","volume":"45","author":"George","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.113245_bib23","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1186\/s12885-022-10379-9","article-title":"Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumour treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial","volume":"22","author":"Schoffski","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2023.113245_bib24","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.22.00294","article-title":"Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumour after treatment with imatinib (INTRIGUE): a randomized, open-label, phase III trial","volume":"40","author":"Bauer","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113245_bib25","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Gastrointestinal Stromal Tumors Version 1.2023. \u00a9 National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed March 17, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. NCCN=National Comprehensive Cancer Network\u00ae (NCCN\u00ae)."},{"key":"10.1016\/j.ejca.2023.113245_bib26","first-page":"125","article-title":"Quality of life research within the EORTC\u2014the EORTC QLQ-C30","volume":"38","author":"Fayers","year":"2002","journal-title":"Eur\u00a0J\u00a0Cancer"},{"key":"10.1016\/j.ejca.2023.113245_bib27","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2307\/2531683","article-title":"A quality-of-Life-oriented endpoint for comparing therapies","volume":"45","author":"Gelber","year":"1989","journal-title":"Biometrics"},{"key":"10.1016\/j.ejca.2023.113245_bib28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2023.113245_bib29","unstructured":"Fayers\u00a0P,\u00a0Aaronson\u00a0NK,\u00a0Bjordal\u00a0K,\u00a0et al. The EORTC QLQ-C30 scoring manual (3rd edition).\u00a0Brussels, European organisation for research and treatment of cancer,\u00a02001."},{"key":"10.1016\/j.ejca.2023.113245_bib30","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.MLR.0000062554.74615.4C","article-title":"Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation","volume":"41","author":"Norman","year":"2003","journal-title":"Med Care"},{"key":"10.1016\/j.ejca.2023.113245_bib31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/00031305.1995.10476135","article-title":"Comparing treatments using quality-adjusted survival: the Q-TWiST method","volume":"49","author":"Gelber","year":"1995","journal-title":"Am Stat"},{"key":"10.1016\/j.ejca.2023.113245_bib32","doi-asserted-by":"crossref","first-page":"S248","DOI":"10.5489\/cuaj.4296","article-title":"Sunitinib toxicity management\u2014a practical approach","volume":"10","author":"Sehdev","year":"2016","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.ejca.2023.113245_bib33","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1200\/JCO.22.01406","article-title":"Ripretinib and the failure to advance GI stromal tumour therapy in the age of precision medicine","volume":"40","author":"Schwartz","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113245_bib34","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/cncr.29220","article-title":"Clinical outcomes of patients with advanced gastrointestinal stromal tumours: safety and efficacy in a worldwide treatment-use trial of sunitinib","volume":"121","author":"Reichardt","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2023.113245_bib35","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1200\/JCO.2011.36.4133","article-title":"Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma","volume":"30","author":"Motzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.113245_bib36","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1002\/cncr.30662","article-title":"Q-TWiST: what really matters to the cancer patient?","volume":"123","author":"Husson","year":"2017","journal-title":"Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923003477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923003477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:41:06Z","timestamp":1760733666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923003477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":36,"alternative-id":["S0959804923003477"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113245","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.113245","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Deciphera Pharmaceuticals LLC. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113245"}}